Last updated on October 2018

A Study to Provide Complementary Efficacy Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting


Brief description of study

This national, open-label study is designed to give complementary efficacy, safety and patient reported outcomes (PROs) data in participants with active relapsing forms of MS. Participants will receive a maximum of 2 treatment cycles of ocrelizumab infusions: an initial dose of two 300 milligram (mg) infusions separated by 14 days followed by one single infusion of 600 mg ocrelizumab 24 weeks after the first infusion. Disease activity is determined by clinical relapses and/or Magnetic Resonance Imaging (MRI) activity.

Clinical Study Identifier: NCT03589105

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: ML40359 ...

Centre hospitalier Annecy Genevois Site St Julien; Neurologie
Metz Tessy, France
  Connect »